Click Diagnostics competitors

Dwight Egan is a President/CEO at CO-DIAGNOSTICS INC. He has worked as Board Member at Watermark Publishing Group, Inc.; Chairman/CEO/Co-Founder at BROADCAST INTERNATIONAL INC; and President/CEO at Watermark Publishing Group, Inc..

Choi Dong-ho (born 26 August 1948) is a South Korean poet, critic, and professor. He studied Korean literature at Korea University at both the undergraduate and graduate levels. He taught Korean literature until his retirement at Korea University, where he is professor emeritus. He published his first poetry collection in 1976, and debuted as a critic when his critical essay won the Joongang Ilbo New Writer’s Contest in 1979. He has written a number of monographs on the spirit of poetry, Eastern poetics, and geukseojeongsi ("extreme lyric poetry"), a term he coined to describe short, easy to understand, and highly evocative poetry. He won the Park Dujin Literary Award in 2009 and the Yushim Award in 2013. Currently, he serves as the president of the Society of Korean Poets and Sisarang Arts and Culture Association.

Jonathan Cohen is the founder and CEO of 20/20 GeneSystems, Inc. (Rockville, MD). 20/20 uses machine learning algorithms together with tumor biomarkers to create the most accurate tests for the early detection of cancer. Our first product is a blood test for the early detection of lung cancer (See www.BloodTestforLungCancer.com). The test is used by primary care physicians to assess the likelihood of lung cancer in patients at a high risk due to age and smoking history. In 2017 20/20 plans to introduce its lung cancer test algorithm in China, home to the world's largest population of smokers. As a seasoned health technology entrepreneur Cohen has raised over $15 million in equity capital and forged and managed license, technology transfer, investment, and sales & marketing agreements with Fortune 500 companies such as Eastman Kodak, Abbott Diagnostics, Johnson & Johnson, and Ping An, the largest health insurance company in China.Mr. Cohen has also been a leading advocate in Annapolis, MD and on Capitol Hill on behalf of small and emerging biotechnology companies. He is the architect of the Maryland Biotechnology Investor Tax Credit, the most aggressive investor incentive in the U.S. Under that program investors in biotech companies like 20/20 receive a 50% refund of their investment from the State of Maryland. Importantly this refund is available to investors who reside outside the State of Maryland. Jonathan also led the legislative effort that resulted in the first increase in funding under the federal Small Business Innovative Research (SBIR) in over 30 years. Specialties: Biotechnology / diagnostics business development; patents and licensing; public advocacy

Hannah Hensel is a Co-Founder & CEO at Brio Device and is based in Ann Arbor, Michigan.